Skip to main content

David L. Bailey

Analyst

Morgan Stanley

Equibles does not estimate personal net worth.

About David L. Bailey

David L. Bailey is recorded as Analyst at Morgan Stanley. David L. Bailey has spoken on 4 earnings calls and 2 other investor events across 3 companies, most recently for Resmed Inc on September 15, 2026. Those appearances were for Resmed Inc (RMD), Telix Pharmaceuticals Ltd (TLX) and Csl Ltd (CSLLY). The companies whose calls David L. Bailey spoke on are classified in the Healthcare sector.

David L. Bailey on recent calls

“Before we begin, there are some disclosures. Please see the Morgan Stanley Research Disclosure website at morganstanley.com forward slash research disclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.”
Analyst — Morgan Stanley, Morgan Stanley Global Healthcare Conference ·
“I'm part of the healthcare team at Morgan Stanley based in Australia. Joined today by Chris Berenbrook and Kevin Richardson, CEO and CEO of Precision Medicine respectively.”
Analyst — Morgan Stanley, Morgan Stanley 24th Annual Global Healthcare Conference ·
“I'm just looking at the guidance commentary again and obviously a fairly significant revenue decline coming through for V4. Essentially, I'm trying to understand the contribution of that in terms of a drag to group impact growth for 27.”
Analyst — Morgan Stanley, CSL Full Year Financial Results 2026 ·
“Reduced component costs has been supportive of gross margins over the past couple of years.”
Analyst — Morgan Stanley, Resmed Inc Q3 FY2026 Earnings Call ·
“It's a follow-on from Dr. Stanton's question. Just from Darren, there was a clear comment there that I think that the investment in growth will consider the commercial performance.”
Analyst — Morgan Stanley, Telix Pharmaceuticals Ltd Q4 FY2025 Earnings Call ·

Affiliation history

  • Morgan Stanley

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity